Magazine Article | March 1, 2022

Post-COVID Supply Chain Opportunities And Strategies For Biopharmas And CDMOs

Source: Life Science Leader

By Derron Stark and Jay Welsh

The COVID-19 pandemic exposed the dependence on global supply chains, as well as the limited domestic manufacturing capacity in the U.S. for critical medicines and medical devices. Recurring drug and medical device shortages and quality issues related to offshoring also have encouraged U.S. commercial customers to purchase from domestic manufacturers. The government policy response has been an intense focus on building up domestic manufacturing capabilities.

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader